Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2026 · third_quarter · Trade (domestic/foreign)
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $7,040,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of
2026 · third_quarter · Trade (domestic/foreign)
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $1,530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102/S. 5316 - Biotech Investment National Security Act
Client expense: $840,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · third_quarter · Health Issues
Issues related to biomanufacturing policy (H.R. 9102 / S. 5316 Biotech Investment National Security Act).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Science/Technology
H.R. 2683, Remote Access Security Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9592, American Space Leadership for the 21st Century Act, all provisions. H.R. 10670, China FIREWALL Act, all provisions. H.R. 10695, United States Submarine Cable Security Policy Act of 2026, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4939, Countering CCP Act, all provisions. S. 5316, Biotech Investment National Security Act (BINSA), all provisions. Issues Related to Adversarial Distillation of American AI Models; Chinese Biotech Industry and Dual-Use Threats; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; National Security Capabilities of Advanced AI Systems; NATO Cybersecurity Capabilities and Strategy; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; TikTok Operations and Safeguards; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy and Regulation; U.S. Cybersecurity Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Open Technology Fund; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy; and U.S. Technology-Security Strategy (no bill).
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Budget/Appropriations
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Financial Institutions/Investments/Securities
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Banking
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Trade (domestic/foreign)
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE